In a press release on April 25, 2008, Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced that under a distribution agreement with Bristol-Myers Squibb Company, the Company has initiated shipments of pravastatin sodium tablets in the 10, 20 and 40 mg. strengths.
Pravastatin sodium distributed by Watson, is the authorized generic version of Bristol-Myers Squibb's Pravachol(R) product and is indicated along with diet to reduce the risk of both first heart attack in patients with elevated cholesterol and recurrent heart attack or a stroke in patients with heart disease, when diet and exercise are not enough. For the 12-months ending December 2005, Pravachol(R) had sales of approximately $1.7 billion, according to IMS Health data.
No comments:
Post a Comment